• Sunshine Biopharma disclosed publication in Journal of Medicinal Chemistry on PLpro inhibitor MR1-114 targeting SARS-CoV-2 variants.
• Study reported nanomolar in vitro potency across multiple variants. Oral dosing showed efficacy in a SARS-CoV-2 mouse model.
• Publication cited high oral bioavailability. Lung enrichment observed in mice, rats.
• Paper: https://pr.report/nwxn

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sunshine Biopharma Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202607200830ACCESSWRNAPR_____1193247) on July 20, 2026, and is solely responsible for the information contained therein.